Business Model & Revenue
DataMeds AI is executing a hard pivot from a low-margin pharmaceutical wholesale distribution model into a high-margin, technology-driven precision health provider. The legacy business generated revenue through bulk pharmaceutical sales, a volume-heavy game that yielded abysmal 10% gross margins and ultimately proved unsustainable.
Today, DataMeds monetizes through two primary high-margin channels. First, the B2B segment charges pharmaceutical companies and researchers for precision oncology CRO services via its newly acquired Helomics CLIA/CAP-certified laboratory. Second, the new B2C segment generates recurring telehealth and digital pharmacy revenue through its "Health Lives Here" mobile app, targeting GLP-1 users via its partnership with Tollo Health. This dual-pronged shift to digital clinical services and AI data analysis structurally alters the company's margin profile, transforming it into an asset-light technology vendor.
Financial Highlights
Full-Year Results (Legacy Wellgistics Health - WGRX)
| Metric | FY 2025 | FY 2024 | YoY% |
|---|---|---|---|
| Revenue | $23.34M | $5.21M | 348.0% |
| Gross Profit | $2.40M | $0.80M | 200.0% |
| Gross Margin | 10.3% | 15.3% | -500 bps |
| Net Income | -$101.27M | -$12.4M | NM |
| Net Margin | -433% | -238% | NM |
| EPS | -$1.05 | -$0.45 | NM |
| Cash | $1.2M | $4.5M | -73.3% |
Quarterly Progression
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| Q2 2026 | $1.78M | -$1.20M | -$0.12 | 24.5% |
| Q1 2026 | $1.52M | -$2.10M | -$0.22 | 18.2% |
| Q4 2025 | $4.10M | -$48.3M | -$0.55 | 6.4% |
| Q3 2025 | $5.80M | -$20.1M | -$0.25 | 8.1% |
Balance Sheet Snapshot
| Item | Amount |
|---|---|
| Total Assets (Q2) | $30.46M |
| Total Debt | $14.20M |
| Total Equity | -$12.45M |
| Shares Outstanding | 2.51M |
The Q2 2026 figures pre-date the September Helomics transaction, which injected an additional $1.5M in cash while acquiring the CLIA lab.
Competitive Landscape
The precision oncology and AI diagnostics sector is rapidly consolidating, with major players attempting to vertically integrate laboratory services with predictive software. DataMeds is entering this space as an underdog but carries the advantage of a fully operational, certified lab from day one.
- Tempus (Private): A massive, well-funded competitor that integrates AI with genomic sequencing. Tempus dominates the institutional market but focuses largely on sequencing rather than functional precision medicine.
- Sema4 (WGS): A health intelligence company that relies heavily on AI to interpret clinical data. While a direct comp, Sema4 has struggled with profitability, highlighting the difficulty of scaling AI diagnostics without strict cost control.
- Lantern Pharma (LTRN): An AI-driven oncology company focusing on drug rescue and development. Lantern is more focused on therapeutics, whereas DataMeds is targeting the CRO and diagnostic service layer.
Competitive Moats:
- CLIA/CAP Infrastructure: The Helomics acquisition provides an immediate, hard-to-replicate regulatory and physical moat. Building and certifying a high-complexity lab from scratch takes years.
- Functional Precision Medicine: By focusing on functional testing (how actual live tumor cells respond to drugs) rather than just genomic sequencing, DataMeds offers actionable, differentiated data to oncologists and CRO clients.
- Turnaround Leverage: With the legacy debt and structural bloat largely written off in 2025, the new management team is operating a lean AI division layered onto a functional lab, minimizing overhead compared to heavily bloated peers.
Catalysts
- Long COVID Platform Expansion: The announced plan to extend the "Health Lives Here" app to Long COVID patients in Q4 2026 provides a near-term growth driver.
- First Helomics Revenue Integration: The Q3 2026 earnings report will be the first to show combined revenues and the new margin profile post-acquisition.
- Direct-to-Consumer Diagnostics: Integration of Helomics diagnostic testing directly into the new mobile app to cross-sell to the existing GLP-1 user base.
- Legacy Business Divestiture: If management successfully spins off or sells the remaining low-margin Wellgistics wholesale assets, it will clarify the pure-play AI thesis.
Not financial advice. For informational purposes only. DYOR. Find alpha where nobody's looking.
Key Risks
- Severe historical unprofitability under the legacy Wellgistics Health brand, including a -$101M net loss in FY2025.
- Integration execution risk as the company attempts to merge a physical CLIA lab with its new digital AI infrastructure.
- Strained balance sheet with negative equity at year-end 2025, suggesting imminent dilution despite the recent $1.5M cash injection.
- Intense competition in the AI-driven precision medicine space from heavily funded private competitors and established diagnostic incumbents.
- Volatile nano-cap trading dynamics; retail momentum could collapse rapidly if clinical adoption metrics stall in upcoming quarters.
Our Thesis
The market historically priced MEDS (formerly WGRX) for bankruptcy, heavily discounting the stock due to a disastrous FY2025. However, the one-two punch of the Helomics lab acquisition and the Tollo Health GLP-1 app launch completely rewrites the narrative. By securing a CLIA-certified lab and a consumer-facing AI health application, management has abruptly transitioned the company into a high-margin, scalable technology tier. The recent Q2 2026 report showing $1.779M in revenue (+14% YoY) indicates the legacy bleeding has stopped, setting a stable floor for the new high-margin digital revenue streams.
Valuing a turnaround nano-cap requires pricing the newly acquired and launched assets. The "Health Lives Here" app provides immediate entry into the massive GLP-1 consumer TAM, while Helomics anchors the B2B precision oncology segment. Assuming the combined digital and diagnostic divisions can generate just $8.0M in annualized revenue by late 2027, and applying a modest 3x EV/Sales multiple, we derive an enterprise value of $24.0M. Accounting for the legacy wholesale cash flows and recent cash injections, our $12.00 price target remains highly defensible for risk-tolerant capital.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.